NEWSROOM
News & Stories
Newsroom
Press Releases
MammaPrintยฎ Reimbursement Indication Extended in Belgium
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ February 11, 2025 โ Agendiaยฎ, Inc. announced today that the National Institute for Sickness and Invalidity Insurance (INAMI-RIZIV) located in Brussels has expanded the reimbursement indication for Read More
Agendia Provides Review of Successful 2024 Advancing the Field of Breast Cancer Treatment
Year-to-Date Achievements Demonstrate Significant Signs of Growth Across All Sectors of Businessย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ January 9, 2025 โ Agendiaยฎ, Inc. today ย provided a topline review of the companyโs key Read More
Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024
Gene expression analysis reveals MammaPrintยฎ as the only commercially available genomic signature that may identify patient subgroups with resistance to CDK4/6 inhibition New real world evidence from FLEX adds to the growing body of Read More
Newsroom
News, Stories & Breast Cancer Blog
What Is Neoadjuvant Chemotherapy?
If you or a loved one has been diagnosed with cancer, your care team may recommend chemotherapy, one of the most common types of cancer treatment available. Chemotherapy involves the use of medications that Read More
What Can We Learn From A Highly Diverse Observational Study Of 17,000+ Breast Cancer Patients?
A conversation with Agendia CMO William Audeh, MD More than 17,000 patients have enrolled in Agendiaโs FLEX trial studying full genome profiling and complete clinical data for those diagnosed with stages I, II, or Read More
How Agendia is personalizing breast cancer treatment
By Abbey Bowling | October 29, 2024 October is Breast Cancer Awareness Month, andย Agendia, one of the leading providers in the field of precision oncology is working to make a significant impact in Read More
How a Pregnant Woman Diagnosed With Breast Cancer Was Helped by MammaPrint
Aleseia Saunders was 32 when she felt a lump in her right breast. Being so young with no family history of breast cancer, she shrugged it off as being a cyst and went on Read More
Laura J. van โt Veer, PhD, Honored With 2024 William L. McGuire Memorial Lecture Award at SABCS 2024
SAN ANTONIO โ Laura J. van โt Veer, PhD, will receive the William L. McGuire Memorial Lecture Award during the San Antonio Breast Cancer Symposium (SABCS) 2024, to be held December 10-13 at the Read More
Gene Assay for MammaPrint May Predict Responses to Extended Letrozole in Low-Risk Breast Cancer Subsets
By Roman Fabbricatore | August 30, 2024 A gene assay was predictive of response to extended letrozole therapy, identifying a subset of patients with low-risk breast cancer with improved outcomes. The 70-Gene MammaPrint (MP) Read More
Personalized Breast Cancer Treatment Offered by Texas Breast Center Utilizes Agendia
Texas Breast Center, led by renowned breast surgeon Dr. Valerie Gorman, is pleased to announce the use of Agendia, a global leader in genomic testing. This collaboration aims to provide patients with the most Read More
